Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.

[1]  G. Salles,et al.  Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier. , 2020, Blood.

[2]  L. Fayad,et al.  A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma , 2019, Blood.

[3]  R. Houot,et al.  Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. , 2019, The Lancet. Haematology.

[4]  J. Gribben,et al.  AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Flinn,et al.  DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Houot,et al.  Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study , 2018, Leukemia.

[7]  K. Papadopoulos,et al.  A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies , 2018, Clinical Cancer Research.

[8]  G. Salles,et al.  Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma , 2018, The New England journal of medicine.

[9]  G. Lenz,et al.  Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Klapper,et al.  Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma , 2017, The New England journal of medicine.

[11]  A. Bhatt International Council for Harmonisation E6(R2) addendum: Challenges of implementation , 2017, Perspectives in clinical research.

[12]  J. Gribben,et al.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. , 2016, The Lancet. Oncology.

[13]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Trotter,et al.  CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. , 2015, Blood.

[15]  S. Barrington,et al.  Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014 , 2015, Leukemia & lymphoma.

[16]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Tuscano,et al.  Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma , 2014, British journal of haematology.

[18]  S. Barrington,et al.  Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012 , 2014, Leukemia & lymphoma.

[19]  R. Chopra,et al.  A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma , 2013 .

[20]  M. Chao Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies , 2013, Cancer management and research.

[21]  H. Tilly,et al.  An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  R. Chopra,et al.  Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression , 2012, British journal of haematology.

[23]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Jeffrey S Barrett,et al.  Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Randy D Gascoyne,et al.  Non-Hodgkin lymphoma , 2016, Medicine.

[27]  J. Kochenderfer,et al.  Chimeric antigen receptor T-cell therapies for lymphoma , 2018, Nature Reviews Clinical Oncology.

[28]  R. Gascoyne,et al.  Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. , 2015, Blood.

[29]  E. Jaffe,et al.  The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. , 2009, Hematology. American Society of Hematology. Education Program.

[30]  G. Salles Clinical features, prognosis and treatment of follicular lymphoma. , 2007, Hematology. American Society of Hematology. Education Program.